Neumora Therapeutics (NMRA) Net Cash Flow (2022 - 2026)

Neumora Therapeutics' Net Cash Flow history runs 5 years deep, the most recent figure standing at -$35.5 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 131.93% year-over-year to -$35.5 million in Q1 2026; TTM through Mar 2026 was $19.0 million, a 133.89% increase from a year earlier, with the FY2025 full-year figure at $39.2 million, up 116.89% from the prior year.
• Net Cash Flow declined to -$35.5 million in Q1 2026 per NMRA's latest filing, from $53.5 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $208.1 million in Q3 2023 and bottomed at -$191.1 million in Q1 2024.
• The 5-year median for Net Cash Flow is -$13.4 million (2022), against an average of -$7.6 million.
• Across the five-year window, Net Cash Flow sank 534.44% in 2024 and soared 140.02% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$11.6 million in 2022, then sank by 230.76% to -$38.2 million in 2023, then plunged by 249.23% to -$133.6 million in 2024, then surged by 140.02% to $53.5 million in 2025, then tumbled by 166.33% to -$35.5 million in 2026.
• Per Business Quant, the three latest NMRA Net Cash Flow figures stand at -$35.5 million (Q1 2026), $53.5 million (Q4 2025), and $4.5 million (Q3 2025).